The advent of ATTR-specific drugs, though pricey, is enabling better survival in these overlapping diseases, researchers say.

Heart failure often follows heart attacks, diabetes, or high blood pressure. However, a very different cause is being ...

Amvuttra is the first and only RNA interference (RNAi) therapeutic approved by the EC for both the cardiomyopathy and the ...

ALNY gains approval to expand Amvuttra's label in the EU, boosting its position as the only RNAi therapy for ATTR-CM.

Carpal tunnel syndrome severely affects your quality of life and capacity to do day-to-day tasks. But can it also be a hint ...

It is important for the nurse to assess the extent of kidney involvement in amyloidosis and the development of the nephrotic syndrome. The nephrotic syndrome is suspected when there are high ...

Alnylam said the green light makes Amvuttra the first and only RNAi therapeutic approved in Europe for the treatment of the cardiomyopathy manifestations of ATTR amyloidosis and the polyneuropathy ...

A new portable device developed by Rutgers University researchers can detect genetic mutations linked to hereditary ...

Aortic valve narrowing (aortic stenosis) with concomitant cardiac amyloidosis is a severe heart disease of old age that is ...

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNA interference (RNAi) therapeutics company, today announced that the European Commission (EC) has granted approval for the treatment of wild ...

Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted ...